The G2 Bio Companies, co-founded by James M. Wilson, MD, PhD, Director, Gene Therapy Program, Rose H. Weiss Professor and Director, Orphan Disease Center and Professor of Medicine and Pediatrics, and the late Tadataka “Tachi” Yamada, MD, PhD, former executive at Takeda Pharmaceuticals and GlaxoSmithKline, launched with a $200 million investment commitment from the global investment firm Temasek to accelerate the development of genetic-based therapies.
G2 Bio funds and develops potential next-generation gene therapy candidates emerging from research conducted at Penn’s Gene Therapy Program (GTP), whose broad research program is working to develop novel therapeutics against more than 50 different diseases and currently managing dozens of translational research projects using a variety of cutting-edge technologies, including gene therapy, gene editing, and mRNA therapeutic approaches using adeno-associated viruses and lipid nanoparticles.
